Publications by authors named "Femke Soetewey"
Background: Evidence suggests that the concordance between amyloid-PET and cerebrospinal fluid (CSF) amyloid-β (Aβ) increases when the CSF Aβ1-42/Aβ1-40 ratio is used as compared to CSF Aβ1-42 levels alone.
Objective: In order to test this hypothesis, we set up a prospective longitudinal study comparing the concordance between different amyloid biomarkers for Alzheimer's disease (AD) in a clinical setting.
Methods: Seventy-eight subjects (AD dementia (n = 17), mild cognitive impairment (MCI, n = 48), and cognitively healthy controls (n = 13)) underwent a [18F]Florbetapir ([18F]AV45) PET scan, [18F]FDG PET scan, MRI scan, and an extensive neuropsychological examination.
Increased brain uptake of F-AV45 visualized by PET is a key biomarker for Alzheimer disease (AD). The SUV ratio (SUVR) is widely used for quantification, but is subject to variability based on choice of reference region and changes in cerebral blood flow. Here we validate the SUVR method against the gold standard volume of distribution (V) to assess cross-sectional differences in plaque load.
View Article and Find Full Text PDFArticle Synopsis
- The study highlights that the buildup of amyloid-β, a marker linked to Alzheimer’s disease, begins long before dementia is diagnosed, emphasizing the need for understanding its prevalence in cognitively healthy individuals and pre-dementia stages for future prevention efforts.
- Researchers conducted a meta-analysis using data from over 10,000 participants to estimate amyloid pathology prevalence across various cognitive states (normal cognition, subjective cognitive impairment, and mild cognitive impairment) based on factors such as age and genetics.
- Findings indicated that amyloid pathology prevalence increases significantly with age, reaching as high as 71% in individuals with mild cognitive impairment, and that carriers of the APOE-ε4 gene have notably higher prevalence